GE & Partners Announce Winners Of the First Stage of $100M "HEALTHYMAGINATION CANCER CHALLENGE"

General Electric announced today five innovation award winners as part  of the first stage of its $100 million "GE healthymagination Cancer Challenge." More than 500 ideas from 40 countries were submitted, sparking robust conversations among more than 200 academic institutions and  researchers on the Challenge's open innovation platform.

The five innovation award winners have the potential to help doctors find cancer earlier, make more accurate diagnoses and choose the best possible treatment based on each patient's unique cancer. The submitted  ideas include ones that could help doctors better understand the molecular similarities between breast cancer and other solid tumors with a particular focus on tumors associated with triple negative cancer, a type of  cancer that is less responsive to standard treatments and is typically more aggressive. GE is committed to a  new approach at healthymagination that shines a spotlight on early-stage ideas to accelerate the researchers' work and ultimately help patients sooner.

Beth Comstock, senior vice president and chief marketing officer, GE said, "We launched the Challenge as a call to action for oncology researchers, businesses, and other innovators around the world to accelerate  innovation and help stop this deadly disease. It is often challenging for early stage research to grab the attention of seed investors. The Challenge has shown us that there are a remarkable number of breakthrough ideas out there that deserve promotion, investment and incubation."

In addition to the $100,000 seed award, GE will provide support for each winner through mentorship and  access to GE researchers and industry thought leaders with opportunity for expanded partnerships in the  future. "GE and Clarient focus on helping health providers understand and define the drivers of a patient's  particular cancer. The Challenge winners' work will change the future of fighting cancer," said Carrie Eglinton-Manner, general manager of Clarient, the cancer diagnostics company acquired by GE in 2010.

"In addition  to the grant money, we will help mentor, develop and accelerate the growth of these winning ideas."

The winners were selected by a panel of judges that included venture capital partners, GE executives, and several leading healthcare luminaries including former U.S. FDA Commissioner and National Cancer Institute  Director, Dr. Andrew Von Eschenbach; Professor of Surgery and Director of the University of Michigan Breast  Care Center, Dr. Lisa Newman; and cancer medicine specialist and Imperial College's professor of cancer medicine, Dr. Justin Stebbing.

The five innovation Challenge award winners are:

• MyCancerGenome- Personalized Approach to Triple Negative Breast Cancer: Vanderbilt University is developing MyCancerGenome, a free online cancer medicine resource and decision-making tool for physicians, patients, caregivers and researchers. It provides up-to-date information on what mutations make breast cancer grow and related treatment implications, including available genome- directed clinical trials for triple negative breast cancer.

• Creating Safer & Stronger Breast Implants with Cancer-fighting and Healing Properties: The University of Akron is developing new materials for breast reconstruction to transform tissue expanders and implants into cancer-fighting and healing devices. Using coatings embedded with pharmaceutical agents the new device is expected to help fight infection, reduce inflammation, and possibly even target and destroy stray cancer cells.

• Identifying a Predisposition to Cancer Spread: Moffitt Cancer Center is working to understand the genetic "modifier" genes and their role in predisposition to the spread of cancer to other parts of the body following cancer onset. This research could form the basis of diagnostic testing for genes that place a patient at disproportionate risk for cancer spread and guide aggressiveness of treatment.

• Saving Lives in Developing Countries: For developing countries such as Uganda, breast ultrasound holds promise in identifying cancers in young women with palpable lumps. Fred Hutchinson Cancer Research Center and Uganda Cancer Institute (UCI) in Kampala are establishing a breast cancer screening program where women will receive education about breast cancer and those with symptoms will be offered clinical breast exam and breast ultrasound. Women with suspicious lumps will be referred to the UCI for tissue sampling and, if malignancy is diagnosed, treatment.

• Moving to Personalized Therapy for Triple Negative Breast Cancer: Researchers at Vanderbilt- Ingram Cancer Center have demonstrated that gene expression analysis reveals at least six distinct disease subtypes for triple negative breast cancer that likely respond differently to chemotherapy. Using this discovery, the Center is designing clinical trials with targeted therapy for select subtypes which will soon be offered to patients.

Information on the winners is available at www.healthymagination.com.